1. Antiviral Strategies Against Chikungunya Virus
- Author
-
Rana Abdelnabi, Johan Neyts, Leen Delang, Chu, JJH, and Ang, SK
- Subjects
0301 basic medicine ,business.industry ,Ribavirin ,030106 microbiology ,virus diseases ,Disease ,Favipiravir ,medicine.disease_cause ,Virology ,Virus ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,chemistry ,Viral replication ,Chloroquine ,medicine ,Chikungunya ,business ,Pathogen ,medicine.drug - Abstract
In the last few decades the Chikungunya virus (CHIKV) has evolved from a geographically isolated pathogen to a virus that is widespread in many parts of Africa, Asia and recently also in Central- and South-America. Although CHIKV infections are rarely fatal, the disease can evolve into a chronic stage, which is characterized by persisting polyarthralgia and joint stiffness. This chronic CHIKV infection can severely incapacitate patients for weeks up to several years after the initial infection. Despite the burden of CHIKV infections, no vaccine or antivirals are available yet. The current therapy is therefore only symptomatic and consists of the administration of analgesics, antipyretics, and anti-inflammatory agents. Recently several molecules with various viral or host targets have been identified as CHIKV inhibitors. In this chapter, we summarize the current status of the development of antiviral strategies against CHIKV infections. ispartof: CHIKUNGUNYA VIRUS: METHODS AND PROTOCOLS pages:243-253 ispartof: Methods in Molecular Biology vol:1426 pages:243-253 ispartof: location:United States status: published
- Published
- 2016
- Full Text
- View/download PDF